27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Main results We included two trials with 26,340 participants aged 40 to 82 years of whom 11,610 were aged 70 or older. 2 key findings →
Design: meta-analysis Participants: 26,340 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Main results We included 39 trials that recruited 16,082 participants, assessing 22 different interventions or comparisons. 4 key findings →
Participants: 39 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Pooling data on over 2.3 million people worldwide, this analysis confirmed that type 2 diabetes raises dementia risk by roughly 60% in both men and women, but the excess risk of vascular dementia specifically was notably higher in women than men. 4 key findings →
Design: meta-analysis Participants: 2,310,330 Evidence: high
Full summary, score breakdown and related studies → Original source
We found no evidence to suggest that the current assumption of constant age-specific prevalence of dementia over time is ill-founded. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The patients receiving regular PPI medication (n = 2950; mean [SD] age, 83.8 [5.4] years; 77.9% female) had a significantly increased risk of incident dementia compared with the patients not receiving PPI medication (n = 70,729; mean [SD] age, 83.0 [5.6] years; 73.6% female) (hazard ratio, 1.44 [95% CI, 1.36-1.52]; P Conclusions and relevance The avoidance of PPI medication may prevent the development of dementia. 2 key findings →
Design: cohort study Participants: 2,950 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
When compared with propofol, dexmedetomidine sedation reduced incidence, delayed onset, and shortened duration of POD in elderly patients after cardiac surgery. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among participants in the Framingham Heart Study, the incidence of dementia has declined over the course of three decades. 3 key findings →
Participants: 5,205 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Studies varied widely in size and quality and therefore we must be circumspect in our conclusions. 3 key findings →
Design: systematic review Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Nineteen studies met our inclusion criteria and quality assessments. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
8 studies examined the association of sedentary behaviour with cognitive function. 6 studies reported significant negative associations between sedentary behaviour and cognitive function. 8 different measures of sedentary behaviour and 13 different measures of cognitive function were used across all eight studies. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The relationship between sensory impairment and cognitive impairment was not unique to one sensory system, suggesting that sensorineural health may be a marker of brain aging. 2 key findings →
Design: longitudinal study Participants: 1,884 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This meta-analysis suggests that hearing impairment is associated with cognitive problems. 5 key findings →
Design: systematic review Participants: 602 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A growing body of evidence suggests that adherence to the Mediterranean diet (MD) may protect against cognitive decline and dementia. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There are cross-sectional evidences of an association between sleep disorders and cognitive impairment on older adults. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This search located 10,338 individual references, of which 164 are included in this review. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
At the First WHO Ministerial Conference on Global Action Against Dementia in March, 2015, 160 delegates, including representatives from 80 WHO Member States and four UN agencies, agreed on a call for action to reduce the global burden of dementia by fostering a collective effort to advance research. 5 key findings →
Participants: 201 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recent findings Both of these leisure-time activities were associated with significant reductions in the risk of dementia in longitudinal studies. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Two decades of epidemiological research shows that silent cerebrovascular disease is common and is associated with future risk for stroke and dementia. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The global burden of ischaemic strokes is almost 4-fold greater than haemorrhagic strokes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The American Heart Association's LS7 score identified individuals who were vulnerable to multiple chronic nonvascular conditions. 4 key findings →
Participants: 6,506 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Suffering related to dementia is multifaceted because cognitive and physical functioning slowly deteriorates. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The A(+)N(-) and A(+)N(+) groups had significantly faster cognitive decline than the A(-)N(-) group (0·08 SD per year for AIBL-Preclinical AD Cognitive Composite [PACC]; p Interpretation Brain amyloidosis, a surrogate marker of Alzheimer's disease pathology, is a risk factor for cognitive decline and for progression from preclinical stages to symptomatic stages of the disease, with neurodegeneration acting as a compounding factor. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Recent findings Anxiety disorders are associated with alterations in fear neurocircuitry such that 'bottom-up' processes in the amygdala which respond to threat are exaggerated, and regulation of these processes by the prefrontal cortex (PFC) and hippocampus is impaired. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Direct oral anticoagulants (DOACs) have been used in clinical practice in the United States for the last 4 to 6 years. 4 key findings →
Participants: 5,254 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Purpose of the study There is a global imperative to increase awareness of the emerging evidence on physical activity (PA) among older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →